ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - location/NSW/2170-Liverpool-Liverpool-Hospital
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
49
trial(s) found.
NCT07764978
Haem
Phase 3
Recruiting
Phase III Open-Label, Randomised Study of Consolidation With AZD0120 (Dual-Targeting BCMA/CD19 CAR-T) vs Continuous Standard Therapy in NDMM Patients Ineligible for ASCT as Initial Therapy (
DURGA-5
)
autologous CAR-T-cell therapy,BCMA/CD19-targeting
Multiple myeloma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2139 - Concord - Concord Repatriation General Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3002 - East Melbourne - Epworth Freemasons
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT07623200
Haem
Phase 3
Recruiting
A Phase 3, Randomized, Open-Label Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia and a CALR Mutation Previously Treated With Cytoreductive Therapy (
EXCALIBUR-ET2
)
anti-CALR monoclonal antibody
Essential thrombocythaemia
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2170 - Liverpool - Liverpool Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4575 - Birtinya - Sunshine Coast University Hospital
WA
6000 - Perth - Royal Perth Hospital
NCT07522073
Advanced
Phase 3
Recruiting
A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma (
DAWN-303
)
KRAS G12D inhibitor,ON/OFF-state inhibitor
Pancreatic adenocarcinoma
NSW
2109 - North Ryde - Macquarie University Hospital
2170 - Liverpool - Liverpool Hospital
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3121 - Richmond - Epworth Freemasons Hospital
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT07492641
Advanced
Phase 3
Recruiting
An Open-Label, Randomized, Multicenter Phase 3 Study Investigating the Efficacy and Safety of BGB-43395 Plus Letrozole Versus CDK4/6 Inhibitors (Abemaciclib, Palbociclib, Ribociclib) Plus Letrozole in Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Systemic Anticancer Treatment for Advanced or Metastatic Disease (
KANDELA-302
)
CDK4/6 inhibitor
CDK4 selective inhibitor
aromatase inhibitor
Breast cancer
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2170 - Liverpool - Liverpool Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4575 - Birtinya - Sunshine Coast University Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
WA
6009 - Nedlands - One Clinical Research
6150 - Murdoch - Fiona Stanley Hospital
NCT07414836
Advanced
Phase 1
Recruiting
A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BG-C0979 in Patients With Selected Advanced Solid Tumors (
BG-C0979-101
)
anti-ADAM9 antibody-drug conjugate
Solid tumour
NSW
2086 - Frenchs Forest - Northern Beaches Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NCT07391657
Haem
Phase 3
Recruiting
A Phase III Open-label, Randomised, Multicentre Study Comparing AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CART) Therapy Directed Against BCMA and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma. (
DURGA-4
)
autologous CAR-T-cell therapy,BCMA/CD19-targeting
Multiple myeloma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2050 - Camperdown - Chris O'Brien Lifehouse
2170 - Liverpool - Liverpool Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT07276399
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants With Treatment-Na\xEFve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (
OrigAMI-5
)
anti-PD-1 monoclonal antibody
bispecific cMET/EGFR antibody
fluoropyrimidine
platinum-based antineoplastic agent
Head and neck squamous cell carcinoma
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT07244705
Advanced
Phase 1 / Phase 2
Recruiting
An Open-label, Multicenter, Phase 1/2 Study Exploring the Safety and Efficacy of ABT-301 in Combination With Tislelizumab and Bevacizumab in Participants With Proficient Mismatch Repair (pMMR)/Non-Microsatellite Instability-High (Non-MSI-H) Locally Advanced or Metastatic Colorectal Cancer (mCRC) (
ABT-301-103
)
HDAC inhibitor
anti-PD-1 monoclonal antibody
anti-VEGF monoclonal antibody
Colorectal adenocarcinoma
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2109 - North Ryde - Macquarie University Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4120 - Greenslopes - Greenslopes Private Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6009 - Nedlands - Linear Clinical Research
NCT07221357
Advanced
Phase 2 / Phase 3
Recruiting
ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer (
CA266-0003
)
anti-VEGF monoclonal antibody
bispecific PD-L1/VEGFA antibody
Colorectal adenocarcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - GenesisCare North Shore Private Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3066 - Epping - Northern Hospital
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
3630 - Shepparton - Goulburn Valley Health
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4120 - Greenslopes - Greenslopes Private Hospital
4575 - Birtinya - Sunshine Coast University Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT07221149
Advanced
Phase 2 / Phase 3
Recruiting
ROSETTA Gastric-204: A Blinded, Randomized, Phase 2/3 Study of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (
CA266-0004
)
anti-PD-1 monoclonal antibody
bispecific PD-L1/VEGFA antibody
Gastric cancer
Gastroesophageal junction adenocarcinoma
NSW
2170 - Liverpool - Liverpool Hospital
VIC
3084 - Heidelberg - Warringal Private Hospital
3168 - Clayton - Monash Medical Centre
QLD
4575 - Birtinya - Sunshine Coast University Hospital
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT07206056
Advanced
Phase 1 / Phase 2
Recruiting
TulmiSTAR-01
: A Two-part, Phase I Dose Escalation and Expansion Followed by a Randomized, Open-label Multicenter, Phase II Study to Assess the Safety and Efficacy of the Combination of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) vs Standard of Care in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer
AR PROTAC degrader
EZH1/2 inhibitor
Castrate-resistant prostate cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT07197827
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Multicenter, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL242 Monotherapy and Combinations in Advanced Solid Tumors. (
YL242-INT-101-01
)
antibody-drug conjugate,VEGF-targeting
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2170 - Liverpool - Liverpool Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT07141706
Advanced
Phase 1
Recruiting
A Phase 1a/1b, Multicenter, Open-Label, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1317 in Participants With Selected Advanced/Metastatic Solid Tumors (
DB-1317-101
)
unknown drug class
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT07110584
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Multi-Center, Open-Label Clinical Study Evaluating MDX2004 In Participants With Advanced Tumors (
MDX-2004-101
)
trispecific-CD28/4-1BB/CD3 fusion protein
Cancer
NSW
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT07063745
Advanced
Phase 2 / Phase 3
Recruiting
A Randomized Phase 2/3 Study of Navlimetostat (BMS-986504) in Combination With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion (
MountainTAP-29
)
PRMT5 inhibitor,MTA-co-operative
anti-PD-1 monoclonal antibody
placebo
Non-small cell lung cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2170 - Liverpool - Liverpool Hospital
ACT
2605 - Garran - The Canberra Hospital
VIC
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4575 - Birtinya - Sunshine Coast University Hospital
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NCT07052903
Haem
Phase 3
Recruiting
TRITON-CM: A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Transthyretin-Mediated Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy) (
ALN-TTRSC04-003
)
placebo
siRNA therapy,TTR-targeting
Transthyretin Amyloidosis
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4032 - Chermside - The Prince Charles Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6027 - Joondalup - Joondalup Health Campus
NZ
NZ.2025 - Papatoetoe - Aotearoa Clinical Trials - Middlemore Hospital
NZ.3210 - Hamilton - Waikato Hospital
NZ.8011 - Christchurch - New Zealand Clinical Research
NCT07005102
Advanced
Phase 2 / Phase 3
Recruiting
A Phase 2/3 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer (
M25-287
)
EGFR inhibitor,third generation
anti-cMET antibody-drug conjugate
Non-small cell lung cancer
Non-squamous non-small-cell lung cancer
NSW
2170 - Liverpool - Liverpool Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
SA
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6150 - Murdoch - St John of God Murdoch Hospital
NCT06953960
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor Surzetoclax (ABBV-453) Given as Monotherapy or in Combination With Antimyeloma Regimens in Subjects With Multiple Myeloma (
M25-275
)
Bcl2 inhibitor
Multiple myeloma
NSW
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3121 - Richmond - Epworth Freemasons Hospital
NCT06926075
Advanced
Phase 1 / Phase 2
Recruiting
An Adaptive Phase I/II Study of KESONOTIDE™, a Novel hGIIA-vimentin Inhibitor, in Participants With Solid Tumours (
ADVICE
)
hGIIA-vimentin inhibitor
Breast cancer
Glioblastoma
Lung cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Skin cancer
NSW
2170 - Liverpool - Liverpool Hospital
2217 - Kogarah - St George Private Hospital
2228 - Miranda - Southside Cancer Care Centre
NCT06898450
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of NDI-219216 in Patients With Advanced Solid Tumors With/Without Microsatellite Instability and/or Deficient Mismatch Repair (
9216-101
)
WRN inhibitor
Cancer
Solid tumour
NSW
2170 - Liverpool - Liverpool Hospital
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT06841055
Advanced
Phase 2
Recruiting
A Phase II, Multisite, Open-label Trial of Pumitamig (BNT327) in Combination With Standard-of-care Chemotherapy in First-line and Second-line Non-small Cell Lung Cancer (NSCLC) (
BNT327-07
)
bispecific PD-L1/VEGFA antibody
Non-small cell lung cancer
NSW
2170 - Liverpool - Liverpool Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Cancer Research SA
WA
6009 - Nedlands - Hollywood Private Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NCT06803680
Advanced
Phase 1
Recruiting
A Phase 1, Open-Label Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B455 in Patients With Selected Advanced or Metastatic Solid Tumors (
BGB-B455-101
)
bispecific T-cell engager,CLDN6-targeting
Solid tumour
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2170 - Liverpool - Liverpool Hospital
NCT06796907
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Randomized Multi-Cohort Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan in Combination With Anti-Cancer Agents in Participants With Advanced Solid Tumors
anti-B7H4 antibody-drug conjugate
Cancer
NSW
2170 - Liverpool - Liverpool Hospital
2500 - Wollongong - Wollongong Hospital
NCT06793215
Advanced
Phase 3
Recruiting
A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Patients With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (
Krascendo-2
)
KRAS G12C inhibitor,OFF-state inhibitor
anti-PD-1 monoclonal antibody
antimetabolite
platinum-based antineoplastic agent
Lung cancer
Non-small cell lung cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4575 - Birtinya - Sunshine Coast University Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT06712355
Advanced
Phase 3
Recruiting
A Phase III, Multisite, Double-blinded Randomized Trial of BNT327 in Combination With Chemotherapy (Etoposide/Carboplatin) Compared to Atezolizumab in Combination With Chemotherapy (Etoposide/Carboplatin) in Participants With First-line Extensive-stage Small-cell Lung Cancer (
BNT327-03
)
anti-PD-L1 monoclonal antibody
bispecific PD-L1/VEGFA antibody
platinum-based antineoplastic agent
topoisomerase inhibitor
Small-cell lung cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2500 - Wollongong - Cancer Care Wollongong
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4870 - Cairns - Cairns Base Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
5037 - Kurralta Park - Icon Cancer Centre Adelaide
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06625593
Advanced
Phase 1
Recruiting
A Phase 1a/b, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C137, an Antibody-Drug Conjugate Targeting FGFR2b, in Patients With Advanced Solid Tumors (
BG-C137-101
)
anti-FGFR2b antibody-drug conjugate
Solid tumour
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2170 - Liverpool - Liverpool Hospital
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NCT06618287
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2a, Open-label, Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BMS-986507 (BL-B01D1) Combinations in Adult Participants With Advanced Solid Tumors (
CA244-0001
)
bispecific EGFR/ERBB3 antibody
Breast cancer
Non-small cell lung cancer
NSW
2170 - Liverpool - Liverpool Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT06615479
Haem
Phase 3
Recruiting
A Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (
CA088-1007
)
autologous CAR-T cell therapy,GPRC5D-targeting
immunomodulatory imide drug
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2170 - Liverpool - Liverpool Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06465953
Haem
Phase 3
Recruiting
A Phase 3, Multicenter, Open Label, Randomized, Non-comparative Two-arm Study of Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Adult Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an Isocitrate Dehydrogenase-1 (IDH1) Mutation (
PyramIDH
Study)
DNA methyltransferase inhibitor
IDH1 R132 inhibitor
antimetabolite
Myelodysplastic syndrome
NSW
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3066 - Epping - Northern Hospital
3168 - Clayton - Monash Medical Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06417814
Advanced
Phase 3
Recruiting
A Phase III, Open-label, Sponsor-blind, Randomized Study of Dato-DXd With or Without Osimertinib Versus Platinum-based Doublet Chemotherapy for Participants With EGFR-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Has Progressed on Prior Osimertinib Treatment (
TROPION-Lung15
)
EGFR inhibitor,third generation
anti-Trop2 antibody-drug conjugate
Non-small cell lung cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2217 - Kogarah - St George Hospital
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06215118
Haem
Phase 1
Recruiting
A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH IBERDOMIDE IN PARTICIPANTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA (
C1071030
)
CELMoD agent
bispecific T-cell engager,BCMA-targeting
Multiple myeloma
NSW
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3002 - East Melbourne - Epworth Freemasons
3121 - Richmond - Epworth Freemasons Hospital
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
NCT06162221
Advanced
Phase 1 / Phase 2
Recruiting
A Platform Study of RAS(ON) Inhibitors in Patients With RAS-Mutated Non-Small Cell Lung Cancer (NSCLC) (
RMC-LUNG-101
)
Carboplatin
Cisplatin
Daraxonrasib
Elironrasib
HRAS inhibitor
KRAS G12C inhibitor
KRAS G12C inhibitor,tricomplex inhibitor
KRAS G12D inhibitor
KRAS G12D inhibitor,tricomplex inhibitor
KRAS inhibitor
KRAS inhibitor,ON-state
KRAS inhibitor,mutant selective
KRAS inhibitor,tricomplex inhibitor
NRAS inhibitor
Pembrolizumab
Pemetrexed
Zoldonrasib
anti-PD-1 monoclonal antibody
antimetabolite
cancer therapy
cancer therapy,KRAS-targeting
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cytotoxic chemotherapy
immune checkpoint blockade
immune checkpoint blockade,PD-1-targeting
immuno-oncology therapy,PD-1-targeting
pan-KRAS inhibitor
pan-RAS inhibitor
pan-RAS inhibitor,tricomplex inhibitor
platinum-based antineoplastic agent
Non-small cell lung cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT06127654
Radonc
Phase 3
Recruiting
VITaL
: A Randomised Controlled Trial Investigating Ventilation Imaging to Improve the Quality of Life for Patients With Lung Cancer Treated With Radiation Therapy
radiotherapy
Lung cancer
NSW
2170 - Liverpool - Liverpool Hospital
NCT06091865
Haem
Phase 3
Recruiting
A Phase 3, Open Label, Randomized Study Comparing the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 \xD7 Anti-CD3 Bispecific Antibody, in Combination With CHOP (ODRO-CHOP) Versus Rituximab in Combination With CHOP (R-CHOP) in Previously Untreated Participants With Diffuse Large B-cell Lymphoma (DLBCL) (
OLYMPIA-3
)
anti-CD20 monoclonal antibody
bispecific T-cell engager,CD20-targeting
Diffuse large B-cell lymphoma
NSW
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3002 - East Melbourne - Epworth Freemasons
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
4217 - Benowa - Pindara Private Hospital
NCT05866458
Curative
Recruiting
Radiation OmisSion in PAtients With CLinically Node Negative Breast Cancer Undergoing Lumpectomy and With a PathologIc Complete REsponse After Neoadjuvant Chemotherapy (
ROSALIE
)
Breast cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2060 - North Sydney - Mater Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2487 - Cudgen - Tweed Valley Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3002 - East Melbourne - Victoria Breast & Oncology Care
3065 - Fitzroy - St Vincent's Hospital Melbourne
3128 - Box Hill - Box Hill Hospital - Eastern Health
3165 - Bentleigh East - Monash Medical Centre - Moorabbin
3844 - Traralgon - Latrobe Regional Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6000 - Perth - Royal Perth Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05797168
Advanced
Phase 1 / Phase 2
Recruiting
A Modular Phase I/IIa, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors (
FONTANA
)
anti-FR-alpha antibody-drug conjugate
Endometrial cancer
Lung adenocarcinoma
Ovarian cancer
Squamous non-small-cell lung cancer
NSW
2170 - Liverpool - Liverpool Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
NCT05785754
Advanced
Phase 1
Recruiting
A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors (
DCSZ11-101
)
anti-CD93 monoclonal antibody
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2031 - Randwick - Scientia Clinical Research Ltd
2076 - Wahroonga - Sydney Adventist Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic
4812 - Townsville - Townsville University Hospital
SA
5011 - Woodville South - The Queen Elizabeth Hospital
5042 - Bedford Park - Southern Oncology Clinical Research Unit
WA
6009 - Nedlands - Linear Clinical Research
NCT05640999
Radonc
Phase 2
Recruiting
A Phase II Study of Tailored Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endormetrial Cancer (RAINBO BLUE & TAPER) (
EN10
)
Radiotherapy
cancer therapy
Endometrial cancer
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
ACT
2605 - Garran - The Canberra Hospital
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3168 - Clayton - Monash Medical Centre
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT05552222
Haem
Phase 3
Recruiting
A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab SC and Lenalidomide (Tal-DR) Versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant as Initial Therapy (
MajesTEC-7
)
anti-CD38 monoclonal antibody
bispecific T-cell engager,BCMA-targeting
bispecific T-cell engager,GPRC5D-targeting
glucocorticoid
immunomodulatory imide drug
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2500 - Wollongong - Wollongong Hospital
VIC
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05519085
Haem
Phase 3
Recruiting
A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM):
SUCCESSOR-1
cereblon E3 ligase modulator
glucocorticoid
immunomodulatory imide drug
proteasome inhibitor
Multiple myeloma
NSW
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2500 - Wollongong - Cancer Care Wollongong
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4575 - Birtinya - Sunshine Coast University Hospital
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit
NZ.9016 - Dunedin - Dunedin Hospital
NCT05067283
Advanced
Phase 1
Recruiting
A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Participants With KRAS G12C Mutant Advanced Solid Tumors (
KANDLELIT-001
)
KRAS G12C inhibitor,OFF-state inhibitor
Colorectal cancer
NOT Non-small cell lung cancer
Non-small cell lung cancer
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3168 - Clayton - Monash Medical Centre
NZ
NZ.8011 - Christchurch - New Zealand Clinical Research
NCT04895709
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors (
CA052-002
)
anti-CCR8 monoclonal antibody
Cervical cancer
Clear cell renal cell carcinoma
Gastroesophageal junction adenocarcinoma
Head and neck squamous cell carcinoma
Melanoma
Microsatellite stable colorectal cancer
Non-small cell lung cancer
Ovarian cancer
Pancreatic adenocarcinoma
Triple-negative breast cancer
Urothelial carcinoma
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2170 - Liverpool - Liverpool Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Nedlands - One Clinical Research
NCT04332822
Haem
Phase 3
Recruiting
R-MINI-CHOP Versus R-MINI-CHP in Combination With Polatuzumab-vedotin, as Primary Treatment for Patients With Diffuse Large B-cell Lymphoma, ≥80 Years, or Frail ≥75 Years - an Open Label Randomized Nordic Lymphoma Group Phase III Trial (
POLAR-BEAR
)
anti-CD79b antibody-drug conjugate
Diffuse large B-cell lymphoma
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
2487 - Cudgen - Tweed Valley Hospital
2640 - Albury - Albury Wodonga Regional Cancer Centre
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
ACT
2605 - Garran - The Canberra Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3065 - Fitzroy - St Vincent's Hospital Melbourne
3066 - Epping - Northern Hospital
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
QLD
4575 - Birtinya - Sunshine Coast University Hospital
WA
6000 - Perth - Royal Perth Hospital
6150 - Murdoch - Fiona Stanley Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT03666000
Haem
Phase 1
Recruiting
A Phase 1/1b, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate Safety and Clinical Activity of PBCAR0191 (Azercabtagene Zapreleucel or "Azer-cel") in Subjects With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) (
PBCAR0191-01
)
allogeneic CAR-T-cell therapy,CD19-targeting
B-cell acute lymphoblastic leukaemia/lymphoma
Chronic lymphocytic leukaemia
Non-Hodgkin's lymphoma
Small Lymphocytic Lymphoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2170 - Liverpool - Liverpool Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT03486873
Advanced
Phase 3
Recruiting
A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants Who Are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab (
3475-587
)
anti-PD-1 monoclonal antibody
Haematological malignancy
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2050 - Camperdown - Royal Prince Alfred Hospital - A.W. Morrow Gastroenterology and Liver Centre
2060 - North Sydney - Mater Hospital
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2109 - North Ryde - Macquarie University Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3021 - St Albans - Western Health - Sunshine Hospital
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4120 - Greenslopes - Greenslopes Private Hospital
4215 - Southport - Gold Coast University Hospital
4215 - Southport - Tasman Oncology
4575 - Sunshine Coast - Sunshine Coast University Private Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5011 - Woodville South - The Queen Elizabeth Hospital
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.3210 - Hamilton - Waikato Hospital
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
ACTRN12625000484448
Curative
Not Applicable
Recruiting
Investigating the use of Stereotactic Ablative Body Radiation (SABR) Dose Escalation and Tri-Modality Treatment in Muscle-Invasive Bladder Cancer (MIBC) on local disease control outcomes. (
Bladder-Boost
)
Radiotherapy
cancer therapy
Bladder cancer
NSW
2170 - Liverpool - Liverpool Hospital
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital
ACTRN12625000429459
Haem
Phase 2
Recruiting
A Centralized Platform study for Functional High Risk Multiple Myeloma - Master Protocol (
ZEPFHR-MM
)
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2139 - Concord - Concord Repatriation General Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3004 - Melbourne, Southbank - Alfred Health
3128 - Box Hill - Box Hill Hospital - Eastern Health
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
ACTRN12623000552684
Curative
Phase 2
Recruiting
OCEANiC
: A Phase II, Open-label, Multi-centre Clinical Trial on effect of Osimertinib, With or Without Adjuvant Chemotherapy, Guided by High-risk Tumour Next Generation Sequencing (NGS) Co-mutation Status and circulating tumour DNA (ctDNA) Detection on disease-free survival in Patients With Stage IIA-IIIA epidermal growth factor receptor (EGFR)-Mutant Non Small Cell Lung Cancer Following Complete Surgical Resection
EGFR inhibitor,third generation
EGFR-mutant non-small cell lung cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4032 - Chermside - The Prince Charles Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
ACTRN12621001458820
Haem
Phase 1
Not yet recruiting
Phase I Clinical Trial to Determine Dosing Schedule of Hydroxychloroquine in Participants with Multiple Myeloma and Partial Response or Less to Carfilzomib (
CHARMM
)
anti-malarial agent
proteasome inhibitor
Cancer
Multiple myeloma
NSW
2170 - Liverpool - Liverpool Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (48)
Not yet recruiting (1)
Recruitment Country and State
NSW (49)
VIC (39)
QLD (29)
WA (28)
SA (17)
NZ (7)
ACT (5)
TAS (4)
Phase
Phase 1 (9)
Phase 1 / Phase 2 (12)
Phase 2 (4)
Phase 2 / Phase 3 (4)
Phase 3 (18)
Trial Type
Advanced (29)
Haem (15)
Curative (3)
Radonc (2)
Cancer Therapy Class
PD-1/PD-L1
37%
PD-1
31%
cereblon
14%
EGFR
12%
VEGF
12%
PD-L1
12%
VEGFA
12%
CD38
10%
proteasome
10%
KRAS
8%
BCMA
6%
MET
4%
GPRC5D
4%
CD20
4%
PARP
4%
CALR
2%
CDK4
2%
CDK4 selective
2%
CDK6
2%
oestrogen axis
2%
HDAC
2%
AR
2%
EZH1
2%
EZH2
2%
androgen axis
2%
PRMT5
2%
Bcl2
2%
hGIIA-vimentin
2%
WRN
2%
CLDN6
2%
B7H4
2%
FGFR2
2%
FGFR2b
2%
ERBB3
2%
DNA methyltransferase
2%
IDH1
2%
IDH1 R132
2%
Trop2
2%
FR-alpha
2%
PARP1-selective
2%
CD93
2%
gp100
2%
CCR8
2%
CD79b
2%
CD19
2%
LAG3
2%
Facility
2170 - Liverpool - Liverpool Hospital (49)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (14)
3000 - Melbourne - Peter MacCallum Cancer Centre (13)
3168 - Clayton - Monash Medical Centre (13)
3065 - Fitzroy - St Vincent's Hospital Melbourne (11)
2050 - Camperdown - Chris O'Brien Lifehouse (11)
4102 - Woolloongabba - Princess Alexandra Hospital (11)
6150 - Murdoch - Fiona Stanley Hospital (10)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (10)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (10)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (9)
4575 - Birtinya - Sunshine Coast University Hospital (8)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (8)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (6)
3004 - Melbourne, Southbank - Alfred Health (6)
5011 - Woodville South - The Queen Elizabeth Hospital (6)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (5)
2605 - Garran - The Canberra Hospital (5)
3128 - Box Hill - Box Hill Hospital - Eastern Health (5)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (5)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (5)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (5)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (5)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (5)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (4)
5112 - Elizabeth Vale - Lyell McEwin Hospital (4)
3021 - St Albans - Western Health - Sunshine Hospital (4)
3066 - Epping - Northern Hospital (4)
7000 - Hobart - Royal Hobart Hospital (4)
2139 - Concord - Concord Repatriation General Hospital (3)
3002 - East Melbourne - Epworth Freemasons (3)
6000 - Perth - Royal Perth Hospital (3)
2109 - North Ryde - Macquarie University Hospital (3)
3121 - Richmond - Epworth Freemasons Hospital (3)
2500 - Wollongong - Wollongong Hospital (3)
2031 - Randwick - Scientia Clinical Research Ltd (3)
4120 - Greenslopes - Greenslopes Private Hospital (3)
6009 - Nedlands - Linear Clinical Research (3)
5042 - Bedford Park - Flinders Medical Centre (3)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (3)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (3)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (3)
6009 - Nedlands - One Clinical Research (2)
2065 - St Leonards - GenesisCare North Shore Private Hospital (2)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (2)
4032 - Chermside - The Prince Charles Hospital (2)
NZ.3210 - Hamilton - Waikato Hospital (2)
NZ.8011 - Christchurch - New Zealand Clinical Research (2)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (2)
2500 - Wollongong - Cancer Care Wollongong (2)
3199 - Frankston - Peninsula Health Frankston Hospital (2)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (2)
2031 - Randwick - Prince of Wales Hospital (2)
2060 - North Sydney - Mater Hospital (2)
2487 - Cudgen - Tweed Valley Hospital (2)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (2)
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (2)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (1)
2086 - Frenchs Forest - Northern Beaches Hospital (1)
3630 - Shepparton - Goulburn Valley Health (1)
3084 - Heidelberg - Warringal Private Hospital (1)
6027 - Joondalup - Joondalup Health Campus (1)
NZ.2025 - Papatoetoe - Aotearoa Clinical Trials - Middlemore Hospital (1)
6150 - Murdoch - St John of God Murdoch Hospital (1)
2217 - Kogarah - St George Private Hospital (1)
2228 - Miranda - Southside Cancer Care Centre (1)
5000 - Adelaide - Cancer Research SA (1)
6009 - Nedlands - Hollywood Private Hospital (1)
4870 - Cairns - Cairns Base Hospital (1)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (1)
2217 - Kogarah - St George Hospital (1)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (1)
4217 - Benowa - Pindara Private Hospital (1)
3002 - East Melbourne - Victoria Breast & Oncology Care (1)
3165 - Bentleigh East - Monash Medical Centre - Moorabbin (1)
3844 - Traralgon - Latrobe Regional Hospital (1)
2076 - Wahroonga - Sydney Adventist Hospital (1)
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic (1)
4812 - Townsville - Townsville University Hospital (1)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (1)
NZ.3112 - Tauranga - Tauranga Hospital, Bay of Plenty Clinical Trials Unit (1)
NZ.9016 - Dunedin - Dunedin Hospital (1)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (1)
2640 - Albury - Albury Wodonga Regional Cancer Centre (1)
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre (1)
2050 - Camperdown - Royal Prince Alfred Hospital - A.W. Morrow Gastroenterology and Liver Centre (1)
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre (1)
3355 - Wendouree - Ballarat Oncology & Haematology Clinical Trials Unit (1)
4215 - Southport - Gold Coast University Hospital (1)
4215 - Southport - Tasman Oncology (1)
4575 - Sunshine Coast - Sunshine Coast University Private Hospital (1)
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital (1)
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital (1)
Cancer Type
Cancer
Solid tumour
Haematological malignancy
Thoracic cancer
Lung cancer
Respiratory tract cancer
Non-small cell lung cancer
Plasma cell disorder
Multiple myeloma
Gastrointestinal cancer
Breast cancer
Upper gastrointestinal cancer
Colorectal cancer
Lower gastrointestinal cancer
Urogenital cancer
Gynaecological cancer
Pancreatic cancer
Pancreatobiliary cancer
Colorectal adenocarcinoma
Ovarian cancer
B-cell lymphoma
B-cell malignancy
Lymphoma
Mature B-cell malignancy
Non-Hodgkin's lymphoma
Myeloproliferative neoplasm
Exocrine pancreatic cancer
Pancreatic adenocarcinoma
Head and neck cancer
Head and neck squamous cell carcinoma
Gastric cancer
Gastric carcinoma
Gastroesophageal cancer
Gastroesophageal junction adenocarcinoma
Oesophageal cancer
Male genital cancers
Prostate cancer
Non-squamous non-small-cell lung cancer
Diffuse large B-cell lymphoma
High-grade B-cell lymphoma
Endometrial cancer
Essential thrombocythaemia
Castrate-resistant prostate cancer
Prostate adenocarcinoma
Amyloidosis
Transthyretin Amyloidosis
Central nervous system cancer
Glioblastoma
Glioma
High-grade glioma
Malignant glioma
Neurological cancer
Skin cancer
Carcinoma
Neuroendocrine carcinoma
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
Myelodysplastic syndrome
Lung adenocarcinoma
Squamous non-small-cell lung cancer
Breast adenocarcinoma
Cervical cancer
Clear cell renal cell carcinoma
HPV-related cancer
HPV16-positive cancer
Kidney cancer
Melanoma
Microsatellite stable colorectal cancer
Non-microsatellite instability-high colorectal cancer
Triple-negative breast cancer
Urothelial carcinoma
Viral-related cancer
Acute lymphoblastic leukaemia
B-cell acute lymphoblastic leukaemia/lymphoma
Chronic lymphocytic leukaemia
Leukaemia
Lymphoid leukaemia
Small lymphocytic lymphoma
Bladder cancer
EGFR-mutant non-small cell lung cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy